ClinicalTrials.gg
CompletedNCT06309953Updated Oct 21, 2025Results posted

A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

A Phase 4 interventional study of Miebo in Dry Eye, sponsored by Bausch & Lomb Incorporated. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-21.

Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
99
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing perfluorohexyloctane in Dry Eye Syndromes — 1 open to participants now, 2 under way, none of them phase 3. perfluorohexyloctane · Dry Eye Syndromes.

Enrollment
10th of 13
99 · median 216
Started
2024
with 2 others
Phase 4
7 of 13
1 open now
Registered
6th of 13
by date
Lead sponsor
9 of 13
Bausch & Lomb Incorporated

Among the 13 studies testing perfluorohexyloctane in Dry Eye Syndromes, this one is the 10th largest by enrollment, is one of 3 that started in 2024, is one of 7 in phase 4, and was the 6th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

1 of the 13 studies testing perfluorohexyloctane in Dry Eye Syndromes is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About perfluorohexyloctane

perfluorohexyloctane: first FDA approval 2023 (MIEBO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing perfluorohexyloctane in Dry Eye Syndromes, or all of them as a file.
02

Study summary

An Open-Label, Multicenter, Phase 4 Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

Read the detailed description

The primary objective of this study is to evaluate early outcomes with Miebo treatment in subjects with Dry Eye Disease (DED)

03

Conditions studied

  • Dry Eye

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years of age at the time of consent
  2. Able to provide written voluntary
  3. The same eye must satisfy the below inclusion criteria (a-e):

    1. Subject-reported history of DED in at least 1 eye for at least 6 months prior to Visit 1
    2. Tear-film break-up time ≤5 seconds at Visit 1
    3. Total corneal fluorescein staining score ≥4 and ≤11 (ie, sum of inferior, superior, central, nasal, and temporal) according to the National Eye Institute scale at Visit 1
    4. Total meibomian gland dysfunction score ≥3 (range, 0-15)
    5. Unanesthetized Schirmer's test I score ≥5 mm
  4. Ocular Surface Disease Index (OSDI) ≥25 at Visit 1
  5. Able and willing to follow instructions, including participation in all trial assessments and visits.

Exclusion criteria

Exclusion Criteria:

Note: Ocular exclusion criteria are relevant to both eyes, such that meeting a criterion in either eye excludes the subject from the study

  1. Had received Miebo as a prescription or as a study treatment in previous Miebo clinical studies
  2. Have any ocular surface slit lamp findings at Visit 1 and/or, in the opinion of the Investigator, have any findings that could interfere with trial parameters, including:

    1. History of eye trauma
    2. History of Stevens-Johnson syndrome
    3. Active blepharitis or lid margin inflammation
    4. DED secondary to scarring, irradiation, alkali burns, cicatricial pemphigoid, or destruction of conjunctival goblet cells (as with vitamin A deficiency)
    5. Abnormal lid anatomy causing incomplete eyelid closure
    6. Abnormal cornea shape (keratoconus)
    7. Corneal epithelial defect or significant confluent or filaments
    8. History of herpetic keratitis
    9. Pterygium
    10. Ocular or periocular rosacea
  3. Use of any of the following ocular therapies within 60 days prior to Visit 1: Vuity®, any topical ocular treatments, prescription dry eye therapy including varenicline nasal spray, or topical anti-glaucoma medication
  4. Had a LipiFlow® procedure, intense pulse light procedure, or any kind of other procedure affecting meibomian glands within 6 months prior to Visit 1
  5. Had received or removed a permanent punctum plug within 3 months (6 months for dissolvable plugs) prior to Visit 1
  6. Use of any eye drops (prescription or over-the counter, such as artificial tears or Lumify®) and/or TrueTear™ device (intranasal tear neurostimulator) within 24 hours prior to Visit 1
  7. Have active ocular allergies or ocular allergies that are expected to be active during the trial period.
  8. Have worn contact lenses within 1 month prior to Visit 1 or planned wear during the study.
  9. Have undergone intraocular surgery or ocular laser surgery within 3 months prior to Visit 1; have undergone refractive surgery within 2 years prior to Visit 1
  10. Have active ocular or systemic infection (bacterial, viral, or fungal), including fever.
  11. Female subjects who are pregnant, nursing, or planning a pregnancy
  12. Female subjects of who are not using an acceptable means of ; acceptable methods of contraception include hormonal (oral, implantable, injectable, or transdermal) contraception; mechanical (spermicide in conjunction with a barrier such as a diaphragm or condom) contraception; intrauterine device; or surgical sterilization of partner. For non-sexually active female subjects, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the trial, she must agree to use adequate birth control as defined above for the remainder of the trial.
  13. Have an uncontrolled systemic disease that, in the opinion of the Investigator, will interfere with the trial
  14. Have a known allergy and/or sensitivity to the study treatment
  15. Use of any oral medications known to cause ocular drying (eg, antihistamines, antidepressants, etc.) on a non-stable regimen within 1 month prior to Visit 1 or is expected to be unstable during the trial
  16. Have taken isotretinoin (eg, Accutane, Myorisan, Claravis, Amnesteem) within 6 months prior to Visit 1
  17. Have corrected visual acuity (VA) worse than or equal to +0.7 logarithm of the minimum angle of resolution (logMAR), as assessed with Snellen chart at Visit 1
  18. Are currently enrolled in an drug or device study or had used an investigational drug or device within 60 days prior to Visit 1.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    Miebo treatment

    Drug: Miebo

Interventions

  • DrugMiebo

    Miebo® (perfluorohexyloctane ophthalmic solution) Dosage: one drop of MIEBO four times daily into each eye Dosage form: Ophthalmic solution: 100% perfluorohexyloctane. Frequency: 4 times daily for 14 days

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline (CFB) in Dry Eye Symptom Severity at Visit 3

    Mean change from baseline (CFB) in dry eye symptom severity at Visit 3 (Day 7 ± 1 day) Scale name: Visual Analog Scale Range: min: 0%, max: 100%; 0% corresponds to "none" and 100% corresponds to "worst severity possible" Intrepretation: VAS is a subjective measurement tool that consists of a horizontal assessment line, of 100 mm (10 cm) length where patients place a vertical mark to indicate the level of perceived severity of symptoms. Higher values indicate worse disease severity, lower values indicate better outcome with treatment

    Time frame: Change from baseline in VAS at Visit 3 (Day 7 ± 1 day)

07

Results

Posted Oct 21, 2025

Participant flow

Participant flow — Overall Study
MilestoneMiebo Treatment
Started99
Completed98
Not completed1

Outcome measures

PrimaryMean Change From Baseline (CFB) in Dry Eye Symptom Severity at Visit 3

Mean change from baseline (CFB) in dry eye symptom severity at Visit 3 (Day 7 ± 1 day) Scale name: Visual Analog Scale Range: min: 0%, max: 100%; 0% corresponds to "none" and 100% corresponds to "worst severity possible" Intrepretation: VAS is a subjective measurement tool that consists of a horizontal assessment line, of 100 mm (10 cm) length where patients place a vertical mark to indicate the level of perceived severity of symptoms. Higher values indicate worse disease severity, lower values indicate better outcome with treatment

Time frame:
Change from baseline in VAS at Visit 3 (Day 7 ± 1 day)
Reported as:
Mean · score on a scale
Mean Change From Baseline (CFB) in Dry Eye Symptom Severity at Visit 3
score on a scaleMiebo Treatment
Mean Change From Baseline (CFB) in Dry Eye Symptom Severity at Visit 3-44.5 ± 25.15

Adverse events

Collected over Assessed for approximately 3.5 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Miebo Treatment0/99 (0%)0/99 (0%)0/99 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Miebo Treatment
<=18 years0
Between 18 and 65 years56
>=65 years43
Sex: Female, Male
Sex: Female, Male(Participants)Miebo Treatment
Female85
Male14
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Miebo Treatment
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American7
White90
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Miebo Treatment
United States99
08

Study locations

7 sites
  • Site 207
    Birmingham, Alabama 35233, United States
  • Site 205
    Petaluma, California 94954, United States
  • Site 203
    Pittsburg, Kansas 66762, United States
  • Site 204
    Stillwater, Minnesota 55082, United States
  • Site 202
    Kansas City, Missouri 64154, United States
  • Site 201
    Brecksville, Ohio 44141, United States
  • Site 206
    Westlake, Ohio 44145, United States
09

References and documents

Publications

  • Bacharach J, Kannarr SR, Verachtert A, Gupta PK, Razeen M, Cavet ME, Vittitow JL, Lang J, Chester TM, Ziemanski JF, White DE. Early Effects of Perfluorohexyloctane Ophthalmic Solution on Patient-Reported Outcomes in Dry Eye Disease: A Prospective, Open-Label, Multicenter Study. Ophthalmol Ther. 2025 Apr;14(4):693-704. doi: 10.1007/s40123-025-01097-z. Epub 2025 Feb 22. PubMed 39985746 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Jun 2024, 3 months.

Results were first posted in Oct 2025, 1 year 4 months after primary completion.

Of 28 industry-sponsored phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 15. This study's 3 months is below that.

Counting every sponsor, half of 112 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2024
First posted
Mar 13, 2024
StartActual
Feb 28, 2024
Primary completionActual
Jun 17, 2024
CompletionActual
Jun 17, 2024
Results first posted
Oct 21, 2025
Last update
Oct 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06309953
Responsible party
Sponsor
First posted
Mar 13, 2024
Start date
Feb 28, 2024
Primary completion
Jun 17, 2024
Completion
Jun 17, 2024
Results posted
Oct 21, 2025
Last update
Oct 21, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Perfluorohexyloctane

Start the discussion